Bioinformatics Institute, Agency for Science, Technology and Research (A*STAR), 30 Biopolis Street, Singapore, 138671, Singapore.
p53 Laboratory, Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Singapore, 138648, Singapore.
Sci Rep. 2019 Jan 24;9(1):693. doi: 10.1038/s41598-018-36589-5.
p53 is frequently mutated in human cancers. Its levels are tightly regulated by the E3 ubiquitin ligase MDM2. The complex between MDM2 and p53 is largely formed by the interaction between the N-terminal domain of MDM2 and the N-terminal transactivation (TA) domain of p53 (residues 15-29). We investigated the kinetic and thermodynamic basis of the MDM2/p53 interaction by using wild-type and mutant variants of the TA domain. We focus on the effects of phosphorylation at positions Thr18 and Ser20 including their substitution with phosphomimetics. Conformational propensities of the isolated peptides were investigated using in silico methods and experimentally by circular dichroism and H-NMR in aqueous solution. Both experimental and computational analyses indicate that the p53 peptides are mainly disordered in aqueous solution, with evidence of nascent helix around the Ser20-Leu25 region. Both phosphorylation and the phosphomimetics at Thr18 result in a decrease in the binding affinity by ten- to twenty-fold when compared to the wild-type. Phosphorylation and phosphomimetics at Ser20 result in a smaller decrease in the affinity. Mutation of Lys24 and Leu25 also disrupts the interaction. Our results may be useful for further development of peptide-based drugs targeting the MDM2/p53 interaction.
p53 在人类癌症中经常发生突变。其水平受到 E3 泛素连接酶 MDM2 的严格调控。MDM2 和 p53 之间的复合物主要由 MDM2 的 N 端结构域和 p53 的 N 端转录激活(TA)结构域(残基 15-29)之间的相互作用形成。我们使用 TA 结构域的野生型和突变变体研究了 MDM2/p53 相互作用的动力学和热力学基础。我们专注于 Thr18 和 Ser20 位置磷酸化的影响,包括它们被磷酸模拟物取代的情况。通过计算方法和在水溶液中的圆二色性和 H-NMR 实验,研究了分离肽的构象倾向。实验和计算分析都表明,p53 肽在水溶液中主要是无规卷曲的,在 Ser20-Leu25 区域周围有新生螺旋的证据。与野生型相比,Thr18 的磷酸化和磷酸模拟物导致结合亲和力降低 10 到 20 倍。Ser20 的磷酸化和磷酸模拟物导致亲和力略有下降。Lys24 和 Leu25 的突变也破坏了相互作用。我们的结果可能对进一步开发针对 MDM2/p53 相互作用的基于肽的药物有用。